Literature DB >> 6629917

Acute effects of intratracheal administration of platelet-activating factor in baboons.

A Denjean, B Arnoux, R Masse, A Lockhart, J Benveniste.   

Abstract

The bronchomotor effect of intratracheal administration of PAF-acether (60 micrograms X kg -1) was investigated in 37 curarized baboons mechanically ventilated with constant volume and frequency. PAF-acether caused an immediate bronchoconstriction as assessed by a marked increase in peak inspiratory pressure with no change in static pulmonary compliance and chest X-rays. There was a concomitant fall in arterial PO2 and a significant increase in ventilated unperfused lung zones. A decrease of circulating platelets and leucocytes was also observed. Local anesthesia with lidocaine and atropine did not prevent PAF-acether-induced bronchoconstriction although both markedly reduced the bronchial response to histamine. Albuterol significantly reduced the bronchial response to PAF-acether. Pretreatment with aspirin (80 mg X kg -1 iv) did not prevent the bronchoconstriction caused by PAF-acether, and intravenous or intratracheal arachidonic acid caused no bronchial response. Thus the role of cyclooxygenase metabolites of arachidonic acid in PAF-acether-induced bronchoconstriction is unlikely. In conclusion, an acute bronchoconstriction probably not triggered by stimulation of irritant receptors of the airways and associated with aggregation of platelet takes place subsequent to intratracheal administration of PAF-acether. These data suggest that PAF-acether might play a role in the pathogenesis of human asthma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6629917     DOI: 10.1152/jappl.1983.55.3.799

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  10 in total

Review 1.  PAF antagonists. Their potential therapeutic role in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

2.  Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs.

Authors:  C P Page; R H Tomiak; S Sanjar; J Morley
Journal:  Agents Actions       Date:  1985-03

3.  Pulmonary platelet kinetics in asthma.

Authors:  P W Ind; A M Peters; F Malik; J P Lavender; C T Dollery
Journal:  Thorax       Date:  1985-06       Impact factor: 9.139

4.  Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics.

Authors:  C Kroegel; H Matthys
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

5.  Bronchial and vascular effects of Paf in the rat isolated lung are completely blocked by WEB 2086, a novel specific Paf antagonist.

Authors:  J Casals-Stenzel; J Franke; T Friedrich; J Lichey
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

6.  Platelet-activating factor causes ventilation-perfusion mismatch in humans.

Authors:  R Rodriguez-Roisin; M A Félez; K F Chung; J A Barberà; P D Wagner; A Cobos; P J Barnes; J Roca
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 7.  Role for platelet-activating factor in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  Decrease of ciliary beat frequency by platelet activating factor: protective effect of ketotifen.

Authors:  L Kahhak; A Roche; C Dubray; C Arnoux; J Benveniste
Journal:  Inflamm Res       Date:  1996-05       Impact factor: 4.575

9.  Lung dendritic cell developmental programming, environmental stimuli, and asthma in early periods of life.

Authors:  Shanjana Awasthi; Bhupinder Singh; Robert C Welliver; Rodney R Dietert
Journal:  J Allergy (Cairo)       Date:  2012-11-07

10.  Antigen-induced generation of lyso-phospholipids in human airways.

Authors:  F H Chilton; F J Averill; W C Hubbard; A N Fonteh; M Triggiani; M C Liu
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.